Able Wealth Management’s Cytokinetics CYTK Stock Holding History

Able Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12	Closed	-$1K	–	179
2023 Q4	$1K	Buy	+12	New	+$435	﹤0.01%	520

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Able Wealth Management's CYTK Position: Q1 2024 in Review

Able Wealth Management sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 12 shares — an estimated $1K sold.

Able Wealth Management first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Able Wealth Management reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
Able Wealth Management sold 12 Cytokinetics shares in Q1 2024, an estimated $1K.
Able Wealth Management first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
Able Wealth Management's Cytokinetics position peaked at $1K in Q4 2023.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.